



# Final - June 23, 2011

## MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center (Building 19), Atlanta, Georgia

June 22-23, 2011

<u>AGENDA ITEM</u>	<u>PURPOSE</u>	<u>PRESIDER/PRESENTER(S)</u>
<b>Thursday, June 23, 2011</b>		
<b>8:00 <u>Unfinished Business</u></b>		Dr. Carol Baker (Chair, ACIP)
<b>8:15 <u>Agency Updates</u></b> CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NVPO, NIH	Information	<i>Ex officio</i> members
<b>8:30 <u>General Recommendations: Febrile Seizures</u></b> · Introduction · Clinical aspects of febrile seizures	Information	Dr. Jeff Duchin (ACIP, WG Chair) Dr. Harry Keyserling (WG Member, SHEA; Emory University School of Medicine)
· Safety data update · Burden of disease information; next steps	Discussion	Dr. Jerome Tokars (CDC/NCEZID) Dr. Andrew Kroger (CDC/NCIRD)
<b>9:45 <u>Break</u></b>		
<b>10:15 <u>Hepatitis B Vaccine</u></b> · Introduction · Update of hepatitis B incidence among persons with diabetes		Dr. Mark Sawyer (ACIP, WG Chair) Ms. Meredith Reilly (CDC/NCHHSTP)
· Cost effectiveness of hepatitis B vaccination among persons with diabetes · Next steps	Information & Discussion	Dr. Tom Hoerger (RTI International) Dr. Trudy Murphy (CDC/NCHHSTP)
<b>11:15 <u>13-valent Pneumococcal Conjugate Vaccine (PCV13)</u></b> · Introduction · Public health and economic impact of PCV13 in US adults $\geq 50$ years of age		Dr. Mike Marcy (ACIP, WG Chair) Dr. David Strutton (Pfizer)
· Current epidemiology of pneumococcal disease in adults · Considerations for PCV13 use among adults; summary of immunogenicity and efficacy; cost-effectiveness studies	Information & Discussion	Dr. Tamara Pilishvilli (CDC/NCIRD) Dr. Tamara Pilishvilli (CDC/NCIRD)
<b>12:35 <u>Lunch</u></b>		
<b>1:45 <u>Influenza</u></b> · Introduction · Influenza vaccine and egg allergies	Information	Dr. Wendy Keitel (ACIP, WG Chair) Dr. John Kelso (Scripps Clinic, University of California, San Diego); Dr. Matthew Greenhawt (University of Michigan Medical School, Ann Arbor); Dr. Matthew Fenton (NIAID, NIH) Dr. Lisa Grohskopf (CDC/NCIRD)
· Proposed recommendations · Intradermal influenza vaccine · Fluzone High Dose update	Vote Information & Discussion	Dr. David Johnson (sanofi pasteur) Dr. David Johnson (sanofi pasteur); Dr. Pedro Moro (CDC/NCEZID)
<b>3:05 <u>Public Comment</u></b>		
<b>3:20 <u>Adjourn</u></b>		

### *Acronyms*

DTaP	Diphtheria, Tetanus, and Acellular Pertussis Vaccine
NCCDPHP	National Center for Chronic Disease Prevention and Health Promotion
NCEZID	National Center for Emerging and Zoonotic Infectious Diseases
NCHHSTP	National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
NCI	National Cancer Institute
NCIRD	National Center for Immunization and Respiratory Diseases
OID	Office of Infectious Diseases
RTI	Research Triangle International
SHEA	Society for Healthcare Epidemiology of America
TBD	To be determined
Tdap	Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
WG	Work Group